Ascentage Pharma Group International
Ascentage Pharma Group International (AAPG) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AAPG · as of Sep 30, 2025
Ownership Breakdown
14
Institutional Holders
▲ 3 vs Q2
$3.69M
Total Inst. Value
▲ $465,761 vs Q2
23.24M
Shares Outstanding
freeFloat 28.38%
94,076
13F Shares Held
▲ 12,305 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AAPG largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
UBS GROUP AG pharmaceutical preparations | 18.3K | 2.15% | 2.15% | $716.19M | Nov 13, 2025 | ▲ 11.0K |
XY CAPITAL LTD pharmaceutical preparations | 18.1K | 2.12% | 2.12% | $707.40M | Nov 14, 2025 | ▲ 12.5K |
POINT72 (DIFC) LTD pharmaceutical preparations | 17.9K | 2.10% | 2.10% | $699.99M | Nov 14, 2025 | ▼ 3.0K |
NEOS INVESTMENT MANAGEMENT LLC pharmaceutical preparations | 10.4K | 1.22% | 1.22% | $412.18M | Nov 7, 2025 | ▼ 5.1K |
TEMA ETFS LLC pharmaceutical preparations | 10.4K | 1.22% | 1.22% | $405.43M | Oct 24, 2025 | ▼ 5.1K |
CITADEL ADVISORS LLC pharmaceutical preparations | 9.7K | 1.13% | 1.13% | $383.09M | Nov 14, 2025 | NEW |
ABC ARBITRAGE SA pharmaceutical preparations | 5.2K | 0.61% | 0.61% | $204.18M | Nov 6, 2025 | NEW |
MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. pharmaceutical preparations | 2.5K | 0.29% | 0.29% | $96.16M | Nov 3, 2025 | NEW |
TOWER RESEARCH CAPITAL LLC (TRC) pharmaceutical preparations | 829 | 0.10% | 0.10% | $32.36M | Nov 14, 2025 | NEW |
ADVISOR GROUP HOLDINGS, INC. pharmaceutical preparations | 220 | 0.03% | 0.03% | $8.48M | Nov 14, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
3
Increased
+23.6K shares6
New Positions
first time holders4
Decreased
−13.9K shares3
Sold Out
fully exitedNet shares change (top 50)
+9.6K
+23.6K / −13.9K
Net new holders
+2
6 new / 3 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AAPG insider trading · insider activity
Source: SEC Form 4
21
Buy transactions
2
Sell transactions
10.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 298,195 | — | — | 298.2K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 298,194 | $6.58 | $1.96M | 298.2K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 214,999 | — | — | 215.0K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 214,988 | $6.58 | $1.41M | 215.0K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 103,365 | — | — | 103.4K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 103,364 | $8.12 | $839.3K | 103.4K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 95,575 | — | — | 95.6K | Form 4 ↗ |
Zhai Yifan Chief Medical Officer | May 20, 2026 | Award | 92,746 | — | — | 92.7K | Form 4 ↗ |
Yang Dajun Chairman and CEO | May 20, 2026 | Award | 298,194 | $6.58 | $1.96M | 298.2K | Form 4 ↗ |
Yang Dajun Chairman and CEO | May 20, 2026 | Award | 214,999 | — | — | 215.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ascentage Pharma Group International (AAPG) is primarily owned by institutional investors, who hold approximately 0.4% of total shares outstanding. Company insiders own approximately 71.62%, while retail and public investors account for the remaining 27.98%.
The largest institutional shareholder of Ascentage Pharma Group International is UBS GROUP AG, holding approximately 18,345 shares — equal to 2.15% of outstanding shares — as of September 30, 2025.
A total of 14 institutional investors currently hold AAPG stock, with a combined institutional value of approximately $3,685,644 as of the most recent 13F filing period.
Frequently asked questions
AAPG ownershipAscentage Pharma Group International (AAPG) is primarily owned by institutional investors, who hold approximately 0.4% of shares. The largest shareholder is UBS GROUP AG with a 2.15% stake. Company insiders hold 71.62%. Data sourced from SEC Form 13F as of September 30, 2025.